47 related articles for article (PubMed ID: 11037802)
21. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
[TBL] [Abstract][Full Text] [Related]
22. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
[TBL] [Abstract][Full Text] [Related]
23. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
[TBL] [Abstract][Full Text] [Related]
25. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and CYP2C19 in longevity.
Bathum L; Andersen-Ranberg K; Boldsen J; Brøsen K; Jeune B
Eur J Clin Pharmacol; 1998 Jul; 54(5):427-30. PubMed ID: 9754988
[TBL] [Abstract][Full Text] [Related]
26. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia.
Roddam PL; Rollinson S; Kane E; Roman E; Moorman A; Cartwright R; Morgan GJ
Pharmacogenetics; 2000 Oct; 10(7):605-15. PubMed ID: 11037802
[TBL] [Abstract][Full Text] [Related]
27. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
28. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
de Leon J; Armstrong SC; Cozza KL
Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetics and psychopharmacotherapy.
Poolsup N; Li Wan Po A; Knight TL
J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
[TBL] [Abstract][Full Text] [Related]
30. Interethnic differences of drug-metabolizing enzymes.
Gaedigk A
Int J Clin Pharmacol Ther; 2000 Feb; 38(2):61-8. PubMed ID: 10706192
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.
Masimirembwa CM; Hasler JA
Brain Res Bull; 1997; 44(5):561-71. PubMed ID: 9365799
[TBL] [Abstract][Full Text] [Related]
32. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
de Leon J
J Clin Psychopharmacol; 2007 Jun; 27(3):241-5. PubMed ID: 17502769
[No Abstract] [Full Text] [Related]
33. Pharmacogenetics of cytochromes P450.
Hasler JA
Mol Aspects Med; 1999; 20(1-2):12-24, 25-137. PubMed ID: 10575648
[No Abstract] [Full Text] [Related]
34. [Genetic polymorphism of drug metabolizing enzymes].
Yokoi T; Kamataki T
Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
[No Abstract] [Full Text] [Related]
35. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance.
Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M
J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940
[TBL] [Abstract][Full Text] [Related]
36. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).
Matchar DB; Thakur ME; Grossman I; McCrory DC; Orlando LA; Steffens DC; Goldstein DB; Cline KE; Gray RN
Evid Rep Technol Assess (Full Rep); 2007 Jan; (146):1-77. PubMed ID: 17764209
[TBL] [Abstract][Full Text] [Related]
37. Poor metabolizers at the cytochrome P450 2C19 loci is at increased risk of developing cancer in Asian populations.
Wang H; Song K; Chen Z; Yu Y
PLoS One; 2013; 8(8):e73126. PubMed ID: 24015291
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
